Rental flat (low- SES) population, hypertension screening (N = 575) | Non-rental flat (higher-SES) population, hypertension screening (N = 614) | ||||||||||
Hypertension screening | Going for regular screening, N (%) | OR (95Â % CI) | p-value | aORa (95Â % CI) | p-value | Hypertension screening | Going for regular screening, N (%) | OR (95Â % CI) | p-value | aORa (95Â % CI) | p-value |
Not on subsidized primary care (CHAS scheme) | 45.1 (125/277) | 1.00 | 0.737 | 1.00 | 0.949 | Not on subsidized primary care (CHAS scheme) | 57.9 (310/535) | 1.00 | 0.181 | 1.00 | 0.503 |
On subsidized primary care (CHAS scheme) | 43.6 (130/298) | 0.94 (0.68–1.31) | 0.99 (0.66–1.47) | On subsidized primary care (CHAS scheme) | 49.4 (39/79) | 0.71 (0.44–1.14) | 0.76 (0.33–1.71) | ||||
Not in proximity to primary care | 53.3 (16/30) | 1.00 | 0.348 | 1.00 | 0.465 | Not in proximity to primary care | 60.3 (167/277) | 1.00 | 0.121 | 1.00 | 0.258 |
In proximity to primary care | 43.9 (239/545) | 0.68 (0.33–1.43) | 0.73 (0.32–1.70) | In proximity to primary care | 54.0 (182/337) | 0.77 (0.56–1.07) | 0.80 (0.55–1.18) | ||||
Not on regular primary care followup | 39.5 (107/271) | 1.00 | 0.029 | 1.00 | 0.172 | Not on regular primary care followup | 40.6 (26/64) | 1.00 | 0.007 | 1.00 | 0.007 |
On regular primary care followup | 48.7 (148/304) | 1.45 (1.04–2.03) | 1.29 (0.90–1.85) | On regular primary care followup | 58.7 (323/550) | 2.08 (1.23–3.52) | 9.34 (1.82–47.85) | ||||
Rental flat (low- SES) population, diabetes screening (N = 744) | Non-rental flat (higher-SES) population, diabetes screening (N = 887) | ||||||||||
Diabetes screening | Going for regular screening, N (%) | OR (95Â % CI) | p-value | aORb (95Â % CI) | p-value | Diabetes screening | Going for regular screening, N (%) | OR (95Â % CI) | p-value | aORb (95Â % CI) | p-value |
Not on subsidized primary care (CHAS scheme) | 49.9 (183/367) | 1.00 | 0.005 | 1.00 | 0.080 | Not on subsidized primary care (CHAS scheme) | 57.4 (413/720) | 1.00 | 0.015 | 1.00 | 0.042 |
On subsidized primary care (CHAS scheme) | 39.5 (149/377) | 0.66 (0.49–0.88) | 0.74 (0.53–1.04) | On subsidized primary care (CHAS scheme) | 67.7 (113/167) | 1.56 (1.09–2.22) | 2.94 (1.04–8.31) | ||||
Not in proximity to primary care | 41.5 (17/41) | 1.00 | 0.748 | 1.00 | 0.083 | Not in proximity to primary care | 54.4 (193/355) | 1.00 | 0.015 | 1.00 | 0.558 |
In proximity to primary care | 44.8 (315/703) | 1.15 (0.61–2.17) | 1.87 (092–3.78) | In proximity to primary care | 62.6 (333/532) | 1.41 (1.07–1.85) | 1.10 (0.79–1.54) | ||||
Not on regular primary care followup | 37.6 (130/346) | 1.00 | <0.001 | 1.00 | 0.009 | Not on regular primary care followup | 66.0 (95/144) | 1.00 | 0.079 | 1.00 | 0.079 |
On regular primary care followup | 50.8 (202/398) | 1.71 (1.28–2.30) | 1.59 (1.12–2.26) | On regular primary care followup | 58.0 (431/743) | 0.71 (0.49–1.04) | 0.37 (0.12–1.12) | ||||
Rental flat (low- SES) population, hyperlipidemia screening (N = 640) | Non-rental flat (higher-SES) population, hyperlipidemia screening (N = 643) | ||||||||||
Hyperlipidemia screening | Going for regular screening, N (%) | OR (95Â % CI) | p-value | aOR (95Â % CI)c | p-value | Hyperlipidemia screening | Going for regular screening, N (%) | OR (95Â % CI) | p-value | aORc (95Â % CI) | p-value |
Not on subsidized primary care (CHAS scheme) | 37.6 (115/306) | 1.00 | 0.213 | 1.00 | 0.931 | Not on subsidized primary care (CHAS scheme) | 46.9 (238/507) | 1.00 | 0.053 | 1.00 | 0.691 |
On subsidized primary care (CHAS scheme) | 32.6 (109/334) | 0.81 (0.59–1.11) | 0.98 (0.67–1.45) | On subsidized primary care (CHAS scheme) | 56.6 (77/136) | 1.48 (1.01–2.16) | 1.22 (0.45–3.30) | ||||
Not in proximity to primary care | 41.4 (12/29) | 1.00 | 0.550 | 1.00 | 0.770 | Not in proximity to primary care | 44.6 (108/242) | 1.00 | 0.088 | 1.00 | 0.825 |
In proximity to primary care | 34.7 (212/611) | 0.75 (0.35–1.61) | 0.88 (0.39–2.01) | In proximity to primary care | 51.6 (207/401) | 1.32 (0.96–1.82) | 1.04 (0.71–1.52) | ||||
Not on regular primary care followup | 28.2 (91/323) | 1.00 | <0.001 | 1.00 | 0.023 | Not on regular primary care followup | 56.8 (67/118) | 1.00 | 0.067 | 1.00 | 0.569 |
On regular primary care followup | 42.0 (133/317) | 1.84 (1.33–2.56) | 1.82 (1.10–3.04) | On regular primary care followup | 47.2 (248/525) | 0.68 (0.46–1.02) | 0.68 (0.19–2.53) | ||||
Rental population (low- SES), colorectal cancer screening (N = 722) | Non-rental flat (higher-SES) population, colorectal cancer screening (N = 866) | ||||||||||
FOBT screening | Going for regular screening, N (%) | OR (95Â % CI) | p-value | aOR (95Â % CI)d | p-value | FOBT screening | Going for regular screening, N (%) | OR (95Â % CI) | p-value | aOR (95Â % CI)d | p-value |
Not on subsidized primary care (CHAS scheme) | 8.7 (30/346) | 1.00 | 0.788 | 1.00 | 0.810 | Not on subsidized primary care (CHAS scheme) | 18.9 (129/682) | 1.00 | 0.016 | 1.00 | 0.348 |
On subsidized primary care (CHAS scheme) | 8.0 (30/376) | 0.91 (0.54–1.55) | 0.93 (0.49–1.74) | On subsidized primary care (CHAS scheme) | 11.4 (21/184) | 0.55 (0.34–0.90) | 0.55 (0.15–1.94) | ||||
Not in proximity to primary care | 18.2 (8/44) | 1.00 | 0.023 | 1.00 | 0.049 | Not in proximity to primary care | 15.9 (56/352) | 1.00 | 0.411 | 1.00 | 0.049 |
In proximity to primary care | 7.7 (52/678) | 0.37 (0.17–0.85) | 0.42 (0.17–0.99) | In proximity to primary care | 18.3 (94/514) | 1.18 (0.82–1.70) | 1.48 (1.01–2.21) | ||||
Not on regular primary care followup | 7.1 (24/337) | 1.00 | 0.344 | 1.00 | 0.450 | Not on regular primary care followup | 11.1 (18/162) | 1.00 | 0.021 | 1.00 | 0.847 |
On regular primary care followup | 9.4 (36/385) | 1.35 (0.79–2.31) | 1.28 (0.67–2.45) | On regular primary care followup | 18.8 (132/704) | 1.85 (1.09–3.12) | 1.14 (0.29–4.54) | ||||
Rental population (low- SES), cervical cancer screening (N = 334) | Non-rental flat (higher-SES) population, cervical cancer screening (N = 421) | ||||||||||
Pap smear screening | Going for regular screening (N %) | OR (95Â % CI) | p-value | aORe (95Â % CI) | p-value | Pap smear screening | Going for regular screening (N %) | OR (95Â % CI) | p-value | aORe (95Â % CI) | p-value |
Not on subsidized primary care (CHAS scheme) | 16.3 (24/147) | 1.00 | 0.566 | 1.00 | 0.372 | Not on subsidized primary care (CHAS scheme) | 26.0 (81/312) | 1.00 | 0.001 | 1.00 | 0.047 |
On subsidized primary care (CHAS scheme) | 19.3 (36/187) | 1.22 (0.69–2.16) | 2.69 (0.68–2.78) | On subsidized primary care (CHAS scheme) | 43.1 (47/109) | 2.16 (1.37–3.41) | 7.93 (1.03–62.51) | ||||
Not in proximity to primary care | 14.3 (2/14) | 1.00 | 1.00 | 1.00 | 0.795 | Not in proximity to primary care | 14.7 (21/143) | 1.00 | <0.001 | 1.00 | <0.001 |
In proximity to primary care | 18.1 (58/320) | 1.33 (0.29–6.10) | 1.24 (0.25–6.29) | In proximity to primary care | 38.5 (107/278) | 3.64 (2.16–6.13) | 3.22 (1.72–5.84) | ||||
Not on regular primary care followup | 14.6 (23/157) | 1.00 | 0.154 | 1.00 | 0.394 | Not on regular primary care followup | 42.3 (44/84) | 1.00 | 0.003 | 1.00 | 0.750 |
On regular primary care followup | 20.9 (37/177) | 1.54 (0.87–2.73) | 1.49 (0.86–3.77) | On regular primary care followup | 26.5 (84/317) | 0.49 (0.31–0.78) | 0.65 (0.04–9.52) | ||||
Rental population (low- SES), breast cancer screening (N = 517) | Non-rental flat (higher-SES) population, breast cancer screening (N = 609) | ||||||||||
Mammogram screening | Going for regular screening (N %) | OR (95Â % CI) | p-value | aORe (95Â % CI) | p-value | Mammogram screening | Going for regular screening (N %) | OR (95Â % CI) | p-value | aORe (95Â % CI) | p-value |
Not on subsidized primary care (CHAS scheme) | 10.2 (24/236) | 1.00 | 0.053 | 1.00 | 0.009 | Not on subsidized primary care (CHAS scheme) | 9.8 (46/469) | 1.00 | 0.001 | 1.00 | 0.006 |
On subsidized primary care (CHAS scheme) | 16.0 (45/281) | 1.68 (0.99–2.86) | 2.33 (1.23–4.41) | On subsidized primary care (CHAS scheme) | 21.4 (30/140) | 2.51 (1.51–4.16) | 6.02 (1.69–21.28) | ||||
Not in proximity to primary care | 25.0 (6/24) | 1.00 | 0.115 | 1.00 | 0.023 | Not in proximity to primary care | 6.6 (16/244) | 1.00 | <0.001 | 1.00 | 0.032 |
In proximity to primary care | 12.8 (63/493) | 0.44 (0.17–1.15) | 0.29 (0.10–0.84) | In proximity to primary care | 16.4 (60/365) | 2.80 (1.57–4.99) | 2.22 (1.08–4.54) | ||||
Not on regular primary care followup | 12.1 (31/257) | 1.00 | 0.439 | 1.00 | 0.855 | Not on regular primary care followup | 19.7 (25/127) | 1.00 | 0.010 | 1.00 | 0.025 |
On regular primary care followup | 14.6 (38/260) | 1.25 (0.75–2.08) | 1.08 (0.48–2.42) | On regular primary care followup | 10.6 (51/482) | 0.48 (0.29–0.82) | 0.10 (0.01–0.75) |